RNF128 (Ring Finger Protein 128), also known as Graf1 or XTP3, is an E3 ubiquitin ligase encoded by the RNF128 gene located on chromosome Xq22.3. The protein plays a critical role in the ubiquitin-proteasome system, where it catalyzes the transfer of ubiquitin to target proteins, marking them for degradation or modifying their function[1]. Originally identified in T cells as a gene induced during T cell activation, RNF128 has since been implicated in various biological processes including immune regulation, endoplasmic reticulum stress responses, and more recently, neurodegenerative disease pathogenesis[2].
| Attribute | Value |
|---|---|
| Gene Symbol | RNF128 |
| Aliases | Graf1, XTP3, GRAF1, Grail |
| Chromosomal Location | Xq22.3 |
| Gene ID | 56221 |
| Protein Class | E3 Ubiquitin Ligase |
| Molecular Weight | ~46 kDa |
| UniProt ID | Q9H6X0 |
RNF128 contains a C3HC4 RING finger domain at its N-terminus, which is characteristic of E3 ubiquitin ligases that facilitate the transfer of ubiquitin from E2 conjugating enzymes to substrate proteins. The protein is primarily localized to the endoplasmic reticulum (ER) and possesses a transmembrane domain that anchors it to ER membranes[1:1].
E3 ubiquitin ligases like RNF128 serve as substrate recognition modules in the ubiquitin-proteasome system[3]. The RING finger domain coordinates two zinc ions and provides a platform for bringing together the E2 ubiquitin-conjugating enzyme and the substrate protein. This proximity enables transfer of ubiquitin from the E2 to lysine residues on the substrate, a critical step in protein degradation signaling[4].
RNF128 is expressed predominantly in:
The gene shows higher expression in neuronal tissues, suggesting specialized functions in neural cells[1:2]. In the brain, RNF128 expression has been detected in both neurons and glia, with particular enrichment in regions associated with learning and memory.
RNF128 belongs to a family of ER-associated E3 ubiquitin ligases that includes:
This family is characterized by the conserved RING finger domain, transmembrane anchor, and proline-rich region, suggesting conserved functions in protein quality control across cell types.
A significant 2026 study demonstrated that RNF128 knockdown attenuates Parkinson's disease-induced mitochondrial dysfunction in neurons by stabilizing the SIRT1 protein[5]. This finding reveals a novel pathway linking RNF128 to neuronal survival in Parkinson's disease.
Conversely, RNF128 knockdown:
The RNF128-SIRT1 axis represents a novel therapeutic target in Parkinson's disease. Several strategies are being explored:
| Strategy | Approach | Status |
|---|---|---|
| RNF128 inhibitors | Small molecules targeting E3 ligase activity | Preclinical |
| RNAi knockdown | siRNA/shRNA to reduce RNF128 expression | Preclinical |
| SIRT1 stabilization | Compounds preventing RNF128-mediated degradation | Preclinical |
| Gene therapy | Viral delivery of RNF128-targeting constructs | Research |
While direct evidence for RNF128 in Alzheimer's disease is limited, the protein's role in the ubiquitin-proteasome system connects it to several AD-relevant pathways[7]:
Amyloid Processing: The ubiquitin-proteasome system is involved in clearance of amyloid precursor protein (APP) and its processing products. Dysregulation of E3 ligases like RNF128 could contribute to amyloid accumulation.
Tau Pathology: Protein quality control mechanisms are critical for clearance of hyperphosphorylated tau. RNF128-mediated ubiquitination may affect tau turnover.
Synaptic Function: Ubiquitin-dependent protein degradation regulates synaptic protein levels and plasticity. RNF128 activity could influence synaptic homeostasis in AD.
Emerging evidence suggests RNF128 may play a role in ALS pathogenesis through:
The protein's function in ER-associated degradation (ERAD) is particularly relevant given the prominent role of ER stress in ALS[8].
RNF128 has been implicated in regulation of neuroinflammation through its effects on immune cell function[9]. The protein modulates:
SIRT1 (Sirtuin 1) is a NAD+-dependent deacetylase with well-established protective roles in neurodegenerative diseases[10]. SIRT1 promotes mitochondrial biogenesis and function through:
RNF128-mediated degradation of SIRT1 represents a novel regulatory mechanism that becomes dysregulated in Parkinson's disease[5:1]. The SIRT1-PGC-1α axis is a critical regulator of mitochondrial biogenesis, and its disruption contributes to dopaminergic neuron vulnerability.
SIRT1 directly deacetylates and activates PGC-1α, the master regulator of mitochondrial biogenesis. When RNF128 ubiquitinates and promotes SIRT1 degradation:
This pathway connects RNF128 overexpression to the mitochondrial dysfunction that characterizes dopaminergic neuron loss in Parkinson's disease.
The ubiquitin-proteasome system (UPS) is the primary mechanism for targeted protein degradation in eukaryotic cells[11]. RNF128 functions within this system as follows:
RNF128 can catalyze different types of ubiquitin chains:
RNF128 is localized to the ER membrane and participates in ER-associated degradation (ERAD)[12]. This pathway handles:
When ER homeostasis is disrupted, the unfolded protein response (UPR) is activated[13]. RNF128 expression can be modulated by UPR signaling, creating a feedback loop between protein quality control and ER stress.
ER stress is a prominent feature of many neurodegenerative diseases:
RNF128 dysregulation may contribute to ER stress-induced neuronal death.
The discovery of RNF128's role in Parkinson's disease opens several therapeutic avenues[14]:
Small molecule inhibitors targeting RNF128 E3 ligase activity could prevent SIRT1 degradation in Parkinson's disease models. Challenges include:
RNAi-based approaches to knockdown RNF128 expression may provide neuroprotection. Viral vectors (AAV) could deliver:
Compounds that inhibit the RNF128-SIRT1 interaction could preserve SIRT1 levels. Known SIRT1 activators include:
RNF128-targeted approaches combined with SIRT1 activators may provide synergistic neuroprotection.
Research on RNF128 has utilized several model systems:
Potential biomarkers related to RNF128 dysfunction:
Key questions remain unanswered:
Grafer CM, et al. RNF128 regulates integrated stress response and immunological signaling. J Biol Chem. 2021. ↩︎
Komander D. The ubiquitin system. Annu Rev Biochem. 2009. ↩︎
Kumar S, et al. Ubiquitin ligase RNFs in protein quality control. Biochim Biophys Acta. 2015. ↩︎
Knockdown of RNF128 attenuated Parkinson's-induced mitochondrial dysfunction in neurons by stabilizing the SIRT1 protein. Experimental Brain Research. 2026. ↩︎ ↩︎
Lim KH, et al. SIRT1 and mitochondrial dysfunction in Parkinson's disease. Free Radic Biol Med. 2022. ↩︎
Mittal S, et al. Ubiquitination in Alzheimer's disease pathogenesis. Acta Neuropathol Commun. 2021. ↩︎
Nakamura N, et al. ER-associated degradation in neurodegenerative diseases. Cell Mol Neurobiol. 2021. ↩︎
Hrdlicka L, et al. RNF128 regulates neuroinflammation in mouse models. J Neuroinflammation. 2022. ↩︎
Wang Y, et al. Targeting SIRT1 for neurodegenerative disease therapy. Pharmacol Res. 2021. ↩︎
Saito R, et al. Ubiquitin-proteasome system dysfunction in Alzheimer's disease. J Neurochem. 2019. ↩︎
Choi J, et al. RNF128 in endoplasmic reticulum stress and unfolded protein response. Cell Stress Chaperones. 2021. ↩︎
Tai HC, et al. ER stress and ubiquitin-proteasome system in neurodegeneration. Nat Rev Neurosci. 2020. ↩︎
Park S, et al. E3 ubiquitin ligases in neurodegenerative diseases: role and mechanisms. Exp Neurobiol. 2017. ↩︎